Generate Biomedicines, Inc. (GENB)

NASDAQ: GENB · Real-Time Price · USD

12.29

+0.48 (4.06%)

At close: Mar 19, 2026, 4:00 PM EDT

12.43

+0.14 (1.16%)

After-hours: Mar 19, 2026, 6:58 PM EDT

Generate Biomedicines Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	31.89	20.46
Revenue Growth (YoY)	55.89%	-
Cost of Revenue	224.7	175.31
Gross Profit	-192.81	-154.85
Selling, General & Admin	42.26	42.09
Operating Expenses	42.26	42.09
Operating Income	-235.07	-196.94
Interest Expense	-1.14	-2.12
Interest & Investment Income	13.66	18.12
Currency Exchange Gain (Loss)	-0.15	-0.08
Other Non Operating Income (Expenses)	-0.11	-0.15
Pretax Income	-222.8	-181.17
Income Tax Expense	0.16	0.21
Earnings From Continuing Operations	-222.97	-181.38
Minority Interest in Earnings	19.81	7.61
Net Income	-203.15	-173.77
Preferred Dividends & Other Adjustments	46.37	40.01
Net Income to Common	-249.52	-213.78
Shares Outstanding (Basic)	50	49
Shares Outstanding (Diluted)	50	49
Shares Change (YoY)	2.77%	-
EPS (Basic)	-4.98	-4.39
EPS (Diluted)	-4.98	-4.39
Free Cash Flow	-204.13	-121.2
Free Cash Flow Per Share	-4.08	-2.49
Operating Margin	-737.04%	-962.60%
Profit Margin	-782.38%	-1044.90%
Free Cash Flow Margin	-640.06%	-592.39%
EBITDA	-221.89	-181.59
D&A For EBITDA	13.18	15.35
EBIT	-235.07	-196.94

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q